The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of trabectedin in pretreated patients with recurrent epithelial ovarian cancer (REOC).
Marco Marinaccio
No relevant relationships to disclose
Emilia Mele
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Valeria Vincenza Fumarulo
No relevant relationships to disclose
Fausta Sozzi
No relevant relationships to disclose
Ettore Cicinelli
No relevant relationships to disclose